{"disease":{"id":"primary-immunoglobulin-a-nephropathy-igan","name":"primary immunoglobulin a nephropathy igan"},"drugs":{"marketed":[{"drug_id":"atrasentan","indication_name":"primary immunoglobulin A nephropathy (IgAN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanrafia","generic_name":"ATRASENTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Vanrafia works by binding to and blocking the activity of a specific receptor involved in the progression of IgAN."},{"drug_id":"atrasentan","indication_name":"primary immunoglobulin A nephropathy (IgAN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanrafia","generic_name":"ATRASENTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Vanrafia works by binding to and blocking the activity of a specific receptor involved in the progression of IgAN."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06994845","title":"Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05534919","title":"Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Everest Medicines (Singapore) Pte. Ltd.","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}